CUMYL-3TMS-PRINACA explained
| Iupac Name: | N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide |
| Width: | 200px |
| Smiles: | C[Si](C)(C)CCCn1nc(C(=O)NC(C)(C)c2ccccc2)c2ccccc12 |
| C: | 23 |
| H: | 31 |
| N: | 3 |
| O: | 1 |
| Si: | 1 |
| Stdinchi: | 1S/C23H31N3OSi/c1-23(2,18-12-7-6-8-13-18)24-22(27)21-19-14-9-10-15-20(19)26(25-21)16-11-17-28(3,4)5/h6-10,12-15H,11,16-17H2,1-5H3,(H,24,27) |
| Stdinchikey: | BFLYAEBVCZMSPK-UHFFFAOYSA-N |
CUMYL-3TMS-PRINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. Along with the related compound ADMB-3TMS-PRINACA that was reported several months earlier, CUMYL-3TMS-PRINACA is one of the only psychoactive drugs ever reported that contains a silicon atom.[1]
Legality
CUMYL-3TMS-PRINACA is illegal in Germany and Italy and has been recommended for control in Sweden.[2] [3]
See also
Notes and References
- Web site: New psychoactive substances - the current situation in Europe . European Drug Report . European Union Drugs Agency (EUDA) . 2024 .
- Web site: Terp G . Yttrande enligt 13 § Lag (2011:111) om förstörande av vissa hälsofarliga missbrukssubstanser . Opinion according to § 13 Act (2011:111) re destruction of certain health hazards substances of abuse . Swedish . Folkhälsomyndigheten (The Public Health Authority) . 26 May 2023 .
- Web site: DECRETO 12 dicembre 2023 . 12 December 2023 . Gazzetta Ufficiale . Update of the tables containing the indication of narcotic and psychotropic substances, pursuant to the decree of the President of the Republic of 9 October 1990, n. 309 and subsequent amendments and additions. Inclusion in Table I of the specific indication of the substances: MDMB-BINACA; N-sec-butyl-pentedrone; CUMIL-3TMS-PRINACA. (23A06995) (GU General Series n.300 of 27-12-2023) . Italian .
